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Autophagy: Evolutionary and pathophysiological insightsMore than four decades ago, in 1963, Dr. de Duve, the Nobel Prize
winning discoverer of lysosomes, coined the name qautophagyq to
describe the massive recruitment of lysosomes and the formation of
vacuoles in hepatocytes after liver perfusion with glucagon [4]. Since
then, autophagy is referred to as a catabolic process that leads to the
degradation of long-lived proteins and organelles via the contribution
of the vacuole in yeast and in plants, and that of lysosomes in other
eukaryotes. Autophagy is a tightly controlled and evolutionarily
conserved process that plays a crucial role in cell homeostasis. Thus
autophagy allows for the adaptation of cells to stressful conditions, as
well as for the removal of protein aggregates and damaged,
potentially harmful cytoplasmic organelles. Thanks to work per-
formed mainly in yeast in the 90s, many components of the core
autophagic machinery have been discovered and then found to be
phylogenetically conserved throughout the eukaryotic kingdom. The
precise function and detailed regulation of all the components of this
machinery are still the subject of febrile and fertile investigation. In
this special issue of Biochimica et Biophysica Acta (BBA) - Molecular Cell
Research, several world-leading experts contribute 15 up-to-date
reviews on evolutionary and pathophysiological aspects of autophagy.
The current series of reviews has been divided into two sections, a ﬁrst
section that deals with the evolution of autophagy and a second one
that discusses the implication of autophagy in the pathogenesis of
disease.
The ﬁrst section of this review series describes the autophagic
process and its regulation in major eukaryotic groups from plants,
amebia, and unicellular fungi to metazoa. Dr. Bassham describes the
autophagic machinery in plants and its role during development, in
the innate immune response against pathogens, and in cellular
senescence. Dr. Kraft and Dr. Reggiori update research on autophagy
in Saccharomyces cerevisiae and its precise regulation by the target of
rapamycin (TOR) kinase pathway. Dr. Golstein focuses on the so-
called qautophagic cell deathq in Dictyostelium discoideum, raising the
question of what regulates the switch from cytoprotective autophagy
to cellular demise accompanied by autophagy. Dr. Galliot reports that
during starvation of Hydra, autophagic vacuoles form in most
myoepithelial cells of this animal in a process that represents
Hydra's main survival strategy in conditions of nutrient stress. An
appropriate regulation of autophagy likewise is also essential for
regeneration in Hydra, as suggested by the fact that the knock-down
of the serine protease inhibitor Kazal-type (SPINK) gene Kazal1
triggers massive autophagy after amputation, thereby compromising
regeneration as well as the survival of the animal. The ﬁrst section of
this series of reviews devoted to the evolution of autophagy also
includes articles on Caenorhabditis elegans (Dr. Tavernarikis) and
Drosophila melanogaster (Dr. Baehrecke), two models that are0167-4889/$ – see front matter © 2009 Published by Elsevier B.V.
doi:10.1016/j.bbamcr.2009.08.001optimally suitable for studying autophagy in normal development
as well as pathological processes including neurodegenerative
diseases and ageing.
The second section of this special issue deals with the role of
autophagy in multiple distinct pathologies including bacterial and viral
infections, cardiovascular and neurodegenerative diseases, and cancer.
This section startswith a review byDr. Simon,who describes autophagy
in various hematopoietic cell types and analyzes its role in several
processes related to host cell defense. As reported byDr. Colombo, some
bacterial pathogens canmanipulate the autophagy process to establish a
persistent infection. Similarly viruses have evolved different strategies
to escape fromand/or exploit the autophagicmachinery, as discussedby
Dr. Levine. Moreover, autophagy can dampen innate immune and
inﬂammatory responses by mechanisms that still remain to be under-
stood in further detail. Dr. Meyer emphasizes the dual role of autophagy
in the cardiovascular system. The autophagic process has cardioprotec-
tive properties in the context of excessive beta-adrenergic stimulation
and ischemia, presumably because autophagy allows for the removal of
damaged organelles including mitochondria. However, excessive
autophagy can lead to the formation of ceroids and ultimately favor
the rupture of atheriosclerotic plaques. Dr. Yue emphasizes the
singularity of autophagy in neurons with a low level of baseline
autophagosome formation and recalls that a considerable number of
studies have uncovered an important role for this process in
neurodegenerative diseases. The importance ofmitophagy, the selective
degradationofmitochondriabyautophagy, in thesediseases is reviewed
by Dr. Tolkovsky, who summarizes the latest developments on the role
of Parkin, a protein mutated in familial forms of Parkinson's disease, in
targetingdamagedmitochondria formitophagy [5]. Finally, two reviews
highlight the role of autophagy in cancer. Dr. Karantza-Wadsworth
reports how defective autophagy due to partial loss of the essential
autophagy regulator Beclin participates in the progression of breast,
ovarian, and prostate tumors. Dr. Kroemer reports the discoveries that
cytoplasmic p53 inhibits autophagy and that mutated p53 protein
accumulating in the cytoplasm of cancer cells can continue to inhibit
autophagy, although it represses the transactivating function of wild
type p53. More generally, it appears that many oncogenes act as
autophagic suppressors. The overall conclusion from these studies is
that the partial invalidation of the autophagic program may play an
important role in oncogenesis and cancer progression.
In aggregate, the idea emerges that the stimulation of autophagy
may be beneﬁcial for a number of pathologies. This idea is consistent
with recent data obtained in Rhesus monkeys showing that caloric
restriction, a process that results in massive stimulation of
autophagy, delays the onset of age-associated pathologies including
diabetes, cancer, cardiovascular diseases, and brain atrophy [1].
Guido Kroemer, M.D. Ph.D. Research Director
INSERM, Institut Gustave Roussy, Villejuif
France. Guido Kroemer is currently a research
director at the French Medical Research
Council (INSERM), and the director of the
Research Unit qApoptosis, Cancer and Im-
munityq at the Institut Gustave Roussy located
in Villejuif, near Paris, France. Prior to joining
the INSERM (1993), Dr. Kroemer was a senior
scientist of the European Community at the
Spanish National Research Council (CSIC), at
the National Center of Molecular Biology (1990–1992), and at the
National Center of Biotechnology (1993). Dr. Kroemer did his post-
doctoral training in the Collège de France, Nogent-sur-Marne (1988–
1989) and at the University of Innsbruck, Austria, after receiving his
Ph.D./M.D. degree at the same university in 1985. He also holds a Ph.
D. in biology (Autonomous University of Madrid, 1992). Guido
Kroemer's team discovered in 1994 that mitochondrial membrane
permeabilization is a critical step in programmed cell death. His
current research focuses on pathogenic derangements of pro-
grammed cell death, the pathophysiology of autophagy, themolecular
perturbations of cancer cell apoptosis, the pharmacological induction
of apoptosis, and the role of immunogenic cell death in anticancer
therapy. Guido Kroemer is the most cited scientist worldwide in the
ﬁeld of cell death as well as in the area of mitochondrial research. He is
member of EMBO, German Academy of Sciences (Leopoldina),
Academia Europaea, and European Academy of Sciences and Arts.
He received the 2006 Descartes Prize, the highest scientiﬁc distinction
of the European Union, for his fundamental discoveries in the ﬁeld of
programmed cell death (apoptosis). He also received one of the
Grands Prix from the French Academy of Sciences in 2007, as well as
the Carus Medal from the German Academy of Sciences.
Jean-Claude Martinou, M.D., Ph.D. Jean-Claude
Martinou is currently a professor and the head
of the Department of Cell Biology at the
University of Geneva, Switzerland. After spe-
cializing in hematology in Toulouse, France in
1986, Dr. Martinou completed his Ph.D. at the
1396 PrefaceConsistently, rapamycin, an inhibitor of the TOR kinase, was found to
extend the lifespan of yeast, nematodes, fruit ﬂies, and recently of
mice [3]. Similarly, spermidine, a novel inducer of autophagy, can
extend the lifespan of yeast, nematodes, fruit ﬂies, and cultured
human cells [2]. Thus the entire ﬁeld of autophagy research has been
experimenting a paradigm shift. Although autophagy, as it occurs in
human cells, has ﬁrst been viewed as a mechanism of cellular self-
destruction, now the notion emerges that autophagy constitutes a
homeostatic process that, after stress, guarantees for the optimal
restoration of the equilibrium state at the cellular and organismal
levels. The future will tell whether this paradigm shift is deﬁnitive or
whether the pendulum will swing back and reveal an essential role
for autophagy in the pathogenic loss of some human cell types, in
speciﬁc diseases.
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